Takeaways The Teva Canada–Samsung Bioepis deal makes Opuviz (aflibercept biosimilar to Eylea) a commercially available, lower‑cost alternative in Canada’s wet AMD, DME, and retinal vein occlusio...
Takeaways: Expanded Canadian partnership positions Organon as the exclusive commercialization partner for Samsung Bioepis’s ustekinumab biosimilar Pyzchiva (Stelara reference), creating a six-pr...
